R & D

R & D

Pharmaceutical research and development updates

GSK’s RSV vaccine approved by MHRAGSK’s RSV vaccine approved by MHRA
GSK’s RSV vaccine approved by MHRA

GSK has announced that the MHRA has authorised its Arexvy respiratory syncytial virus (RSV) vaccine for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults over the age of 60.

Aug 24, 2023 R & D
RNAi treatment for hypertension developed by Alnylam and RocheRNAi treatment for hypertension developed by Alnylam and Roche
RNAi treatment for hypertension developed by Alnylam and Roche

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension in patients with high cardiovascular risk.

Aug 24, 2023 R & D
GSK’s novel gonorrhoea vaccine gains Fast Track designation from FDAGSK’s novel gonorrhoea vaccine gains Fast Track designation from FDA
GSK’s novel gonorrhoea vaccine gains Fast Track designation from FDA

GSK has announced that the FDA has granted fast track designation for its investigational vaccine for gonorrhoea, which is currently in an ongoing phase 2 trial assessing the efficacy of the vaccine in healthy adults aged 18 to 50 who are considered at risk of contracting gonorrhoea.

Aug 24, 2023 R & D
Data from Eli Lilly’s two phase 3 tirzepatide studies sharedData from Eli Lilly’s two phase 3 tirzepatide studies shared
Data from Eli Lilly’s two phase 3 tirzepatide studies shared

Eli Lilly has announced results from its two phase 3 tirzepatide studies in adult patients with obesity or who are overweight with weight-related comorbidities, excluding type 2 diabetes.

Aug 24, 2023 R & D
Study shows Wegovy by Novo Nordisk reduces cardiovascular riskStudy shows Wegovy by Novo Nordisk reduces cardiovascular risk
Study shows Wegovy by Novo Nordisk reduces cardiovascular risk

Novo Nordisk has shared results from the select cardiovascular outcomes trial, which show that a once-weekly subcutaneous dose of Wegovy (semaglutide 2.4mg) reduced the risk of major adverse cardiovascular events (mace) by 20% in overweight or obese adults over the age of 45 with established cardiovascular disease (CVD) and no prior history of diabetes.

Aug 24, 2023 R & D
First official long COVID-19 treatment could emerge from the NIH’s RECOVER initiativeFirst official long COVID-19 treatment could emerge from the NIH’s RECOVER initiative
First official long COVID-19 treatment could emerge from the NIH’s RECOVER initiative

As of 31 July 2023, the NIH launched the first trials of its ‘researching COVID to enhance recovery’ (RECOVER) initiative.

Aug 24, 2023 R & D
Phase 3 trial results for datopotamab deruxtecan for NSCLC treatment announced by AstraZenecaPhase 3 trial results for datopotamab deruxtecan for NSCLC treatment announced by AstraZeneca
Phase 3 trial results for datopotamab deruxtecan for NSCLC treatment announced by AstraZeneca

AstraZeneca has announced results from its tropion-lung01 phase 3 trial for its trop2-directed antibody drug conjugate, developed in collaboration with daiichi sankyo.

Aug 24, 2023 R & D
Phase 2 trial data from GBS maternal vaccine candidate shared by PfizerPhase 2 trial data from GBS maternal vaccine candidate shared by Pfizer
Phase 2 trial data from GBS maternal vaccine candidate shared by Pfizer

Pfizer has announced new data from its phase 2 study, which assessed its hexavalent capsular polysaccharide conjugate group b streptococcus vaccine candidate, gbs6, in development for maternal vaccination in order to protect infants against invasive GBS disease.

Aug 24, 2023 R & D
Breast cancer treatment phase 3 trial results shared by MerckBreast cancer treatment phase 3 trial results shared by Merck
Breast cancer treatment phase 3 trial results shared by Merck

Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 trial, which assessed Keytruda in combination with chemotherapy for the treatment of patients with high-risk, early-stage oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (er+/her2-) breast cancer.

Aug 24, 2023 R & D
Data shared by Sanofi about new drug for treatment of haemophilia A in childrenData shared by Sanofi about new drug for treatment of haemophilia A in children
Data shared by Sanofi about new drug for treatment of haemophilia A in children

Sanofi has shared new data from the phase 3 xtend-kids study, which assessed Altuviiio (antihemophilic factor (recombinant), fc-vwf-xten fusion protein) once-weekly prophylaxis in patients under the age of 12 with previously treated severe haemophilia A.

Aug 24, 2023 R & D
New Crohn’s disease treatment could come from neonatal stem cells, research showsNew Crohn’s disease treatment could come from neonatal stem cells, research shows
New Crohn’s disease treatment could come from neonatal stem cells, research shows

Recent studies have discovered that human neonatal cardiac-derived mesenchymal stem cells can induce wound-healing and reduce inflammation in the digestive system, caused by Crohn’s disease.

Aug 24, 2023 R & D
AI-enabled drug discovery developments trigger partnership between Recursion and NVIDIAAI-enabled drug discovery developments trigger partnership between Recursion and NVIDIA
AI-enabled drug discovery developments trigger partnership between Recursion and NVIDIA

Clinical stage biotech company Recursion has announced a $50m investment by NVIDIA, intended to accelerate the development of its AIfoundation models for biology and chemistry, working in collaboration with NVIDIA to optimise and distribute these ai models to biotechnology companies through NVIDIA's cloud services.

Aug 24, 2023 R & D